MONDAY, Feb. 11 (HealthDay News) -- Researchers have confirmed previously identified genetic variants and found new variants associated with prostate cancer, according to three studies published online Feb. 10 in Nature Genetics.
In the first study, Gilles Thomas, M.D., Ph.D., from the National Institutes of Health in Bethesda, Md., and colleagues tested 26,958 single nucleotide polymorphisms (SNPs) on a total of 3,941 cases of prostate cancer and 3,964 controls. The investigators found three previously confirmed loci on chromosomes 8 and 17, as well as four additional highly significant loci on chromosomes 7, 10 and 11. Nine loci showed highly suggestive associations.
In the second study, Julius Gudmundsson from deCODE Genetics in Reykjavik, Iceland, and colleagues performed a genome-wide SNP association study for prostate cancer on over 23,000 Icelanders. The team found two newly identified variants on chromosomes X and 2 significantly associated with prostate cancer (odds ratios 1.23 and 1.15, respectively). The chromosome 2 variant was more strongly associated with more aggressive forms of prostate cancer.
In the third study, Rosalind A. Eeles, Ph.D., from the Institute of Cancer Research in Sutton, United Kingdom, and colleagues performed a genome-wide association study of 541,129 SNPs on 1,854 patients with prostate cancer diagnosed at 60 years of age or younger or with a family history of the disease and 1,894 controls. They found loci significantly associated with prostate cancer on chromosomes 3, 6, 7, 10, 11, 19 and X, which was confirmed in an independent population.
"The results of this study confirm that prostate cancer is genetically complex and help clarify the genetic architecture of prostate cancer," Eeles and colleagues write.
Abstract - Thomas
Full Text (subscription or payment may be required)
Abstract - Gudmundsson
Full Text (subscription or payment may be required)
Abstract - Eeles
Full Text (subscription or payment may be required)
